Tislelizumab Combined With Axitinib in Neoadjuvant Treatment of Locally Advanced Clear Cell Renal Cell Carcinoma: A Single-Center, Phase II Clinical Study.

MedComm (2020) · 2026 · PMC12914081 · PMID 41716961

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In our study, eight patients with tumor thrombi showed a trend toward thrombus shrinkage after treatment, and surgery was successfully completed with negative resection margins.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.